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c-Src Links a RANK/v3 Integrin Complex to the Osteoclast
Cytoskeleton
Takashi Izawa,a Wei Zou,a Jean C. Chappel,a Jason W. Ashley,c Xu Feng,c and Steven L. Teitelbauma,b
Department of Pathology and Immunologya and Department of Medicine, Division of Bone and Mineral Diseases,b Washington University School of Medicine, St. Louis,
Missouri, USA, and Department of Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USAc
RANK ligand (RANKL), by mechanisms unknown, directly activates osteoclasts to resorb bone. Because c-Src is key to organiz-
ing the cell’s cytoskeleton, we asked if the tyrosine kinase also mediates RANKL-stimulated osteoclast activity. RANKL induces
c-Src to associate with RANK369 –373 in anv3-dependent manner. Furthermore, RANK369 –373 is the only one of six putative
TRAF binding motifs sufficient to generate actin rings and activate the same cytoskeleton-organizing proteins as the integrin.
While c-Src organizes the cell’s cytoskeleton in response to the cytokine, it does not participate in RANKL-stimulated osteoclast
formation. Attesting to their collaboration, v3 and activated RANK coprecipitate, but only in the presence of c-Src. c-Src
binds activated RANK via its Src homology 2 (SH2) domain and v3 via its SH3 domain, suggesting the kinase links the two
receptors. Supporting this hypothesis, deletion or inactivating point mutation of either the c-Src SH2 or SH3 domain obviates
the RANK/v3 association. Thus, activated RANK prompts two distinct signaling pathways; one promotes osteoclast forma-
tion, and the other, in collaboration with c-Src-mediated linkage to v3, organizes the cell’s cytoskeleton.
Osteoclasts are unique bone resorptive cells, necessary formaintaining skeletal homeostasis. A relative excess of their
activity however, often eventuates in the common disorder osteo-
porosis. Thus, understanding the means by which osteoclasts re-
sorb bone carries both physiological and clinical significance.
The magnitude of skeletal resorption reflects osteoclast num-
ber and the matrix-degrading capacity of the individual cell. Os-
teoclast abundance is governed by macrophage colony-stimulat-
ing factor (M-CSF) and receptor activator of nuclear factor B
ligand (RANKL) interacting with their respective receptors, c-fms
andRANK, onmonocyte/macrophage precursors. In fact, the two
cytokines, in combination, are sufficient for osteoclast formation
in vitro and in vivo.
The capacity of the mature osteoclast to resorb bone is largely
dictated by cytoskeletal organization. Upon contact with miner-
alized substrate, the cell polarizes its resorptive machinery to its
interface with bone and secretes skeleton-degrading molecules
into a microenvironment isolated from the general extracellular
space by “gasket-like” structures known as actin rings or sealing
zones. The ability of osteoclasts to optimally resorb bone depends
upon actin ring formation (reviewed in reference 25).
In 1991, Soriano et al. observed that the principal phenotype of
c-Src-deleted mice resides in the skeleton (24). These animals de-
velop severe osteopetrosis despite an abundance of osteoclasts.
Thus, the disorder does not reflect failed osteoclast recruitment
but defective function, specifically disorganization of the actin
cytoskeleton (2). In fact, c-Src is the dominant Src family kinase
expressed in the osteoclast and regulates the cell’s cytoskeleton as
an adaptor protein and through its enzymatic activity (7, 19, 23).
The integrin v3 is a key regulator of the osteoclast cytoskel-
eton but does not promote osteoclastogenesis (18). Upon v3
occupancy, c-Src is activated, leading to phosphorylation of Syk,
whose recruitment to the integrin-stimulated signaling complex
requires the costimulatory ITAMprotein, Dap12 (29). Alongwith
the adaptor, Slp-76, activated Syk phosphorylates the relatively
osteoclast-specific guanine nucleotide exchange factor (GEF)
Vav3, which transits the Rho GTPase, Rac, from its inactive GDP-
to its active GTP-bound form (8, 9, 22). By impacting the Arp2/3
complex, Rac organizes the osteoclast cytoskeleton, including ef-
ficient actin ring configuration (6). Deletion of any of the signal-
ing molecules in the v3-activated sequence compromises the
ability of osteoclasts to remodel their cytoskeleton and resorb
bone.
During these studies, we found that M-CSF, which promotes
proliferation of osteoclast precursors and inhibits apoptosis of the
mature polykaryon, also organizes its cytoskeleton in a manner
similar to that of the integrin (8, 30). In the present exercise, we
turn to the key osteoclastogenic cytokine RANKL, whose absence
in vivo obviates osteoclast formation. By mechanisms previously
unknown, RANKL also organizes the cytoskeleton of mature re-
sorptive cells, thereby stimulating their capacity to degrade bone
(3). We find that RANKL’s ability to optimally rearrange the os-
teoclast cytoskeleton depends upon induction of its receptor’s as-
sociation with c-Src, which links RANK to the v3 integrin. The
receptor/kinase complex activates the cytoskeleton-organizing
molecules Syk, Slp-76, Vav3, and Rac, which are also induced by
v3. Despite the capacity of the tyrosine kinase to recognize
TRAF6, c-Src-mediated induction of RANK to organize its cyto-
skeleton is independent of its osteoclastogenic signaling pathway.
Thus, c-Src links RANK and v3 and permits the complex to
organize the osteoclast cytoskeleton.
MATERIALS AND METHODS
Mice. Animals were housed in the animal care unit of the Washington
University School of Medicine and were maintained according to guide-
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lines of the Association for Assessment and Accreditation of Laboratory
Animal Care International. All animal experimentation was approved by
the Animal Studies Committee ofWashington University School ofMed-
icine.
Reagents. Glutathione S-transferase (GST)–RANKL was expressed in
our laboratory as described previously (14). RecombinantmurineM-CSF
was obtained fromR&D Systems (Minneapolis, MN). Anti-Fas activating
(CH11) antibody was from Upstate Biotechnology (Charlottesville, VA).
The sources of antibodies are as follows: mouse anti-RANK monoclonal
antibody (MAb) (IMG-128A) was from Imgenex (San Diego CA); MAb
327, directed against the c-Src protein, was a gift from A. Shaw (Depart-
ment of Pathology,Washington University School ofMedicine, St. Louis,
MO);mouse anti-FLAGM2MAbwas from Sigma (St. Louis,MO); rabbit
antihemagglutinin (anti-HA) antibody was from Covance (Princeton,
NJ); rabbit anti-Src p-Y416, rabbit anti-3-integrin, IB, phosphory-
lated IB, extracellular signal-regulated kinase (ERK), phosphorylated
ERK, p38, phosphorylated p38, and rabbit anti-SLP-76 antibodies were
from Cell Signaling (Beverly, MA); antiphosphotyrosine MAb 4G10 and
rabbit anti-Vav3 antibody were fromUpstate Biotechnology; mouse anti-
NFATc1 and rabbit anti-Syk (N-19) antibody were from Santa Cruz Bio-
technology (Santa Cruz, CA); cathepsin K antibody was from Millipore
(Temecula, CA); mouse anti-CD95 antibody, was from BD Biosciences
(Franklin Lakes, NJ); and rabbit anti-TRAF6was fromEnzo Life Sciences.
The plasmid transfection reagent FuGENE 6 was purchased from Roche
Applied Science. All other chemicals were obtained from Sigma.
Macrophage isolation and osteoclast culture. Isolated bone marrow
macrophages (BMMs) and splenocytes were differentiated into mature,
multinucleated osteoclasts as described previously (10). Following 6 days
of culture in M-CSF (30 ng/ml) and GST-RANKL (100 ng/ml), cells were
stained for tartrate-resistant acid phosphatase (TRAP) activity (kit 387-A;
Sigma). For prefusion osteoclast generation, BMMs or splenocytes were
cultured in M-CSF and GST-RANKL for 3 days.
Staining of bone resorption pits. BMMs were plated on bone slices
and cultured with M-CSF and RANKL for 6 days to generate mature
osteoclasts. The cells were then removed frombone slices withmechanical
agitation. Bone slices were incubated with peroxidase-conjugated wheat
germ agglutinin (Sigma) for 1 h and stained with 3,3=-diaminobenzidine
(Sigma).
Actin ring reformation assay. Mature osteoclasts, generated by expo-
sure of bone-slice-residing BMMs to RANKL andM-CSF for 5 days, were
washed twice with cold cytokine-free medium to disrupt actin rings fol-
lowed by incubation at 37°C for 30 min. RANKL (100 ng/ml) was then
added for the indicated time. Bone slices were fixed with 4% paraformal-
dehyde in phosphate-buffered saline (PBS) for 20min. F-actinwas stained
with Alexa Fluor 488-phalloidin.
Plasmids and retroviral transduction. c-Src-pMX-IRES-BSR was
subcloned from c-Src-pMX-IRES-PURO, which contains a puromycin
resistance sequence, into pMX-IRES-BSR by introducing the BamHI 5=
and XhoI 3= restriction sites with a FLAG tag at the 3= end. The MYR
(76), SH3 (81-142), and SH2 (148-245) constructs were gener-
ated by standard molecular biology techniques. A total of 10 g of the
pMX retroviral vector was transfected transiently into Plat-E packaging
cell line (20), using FuGENE 6 transfection reagent (Roche Applied Sci-
ence). Virus was collected 48 h after posttransfection. BMMs or spleno-
cytes were infectedwith virus for 24 h in the presence of 100 ng/mlM-CSF
and 4 g/ml Polybrene (Sigma). Cells were selected in the presence of
M-CSF and 1 g/ml blasticidin (Calbiochem) for 3 days prior to use as
osteoclast precursors.
Western blotting and immunoprecipitation. Forty micrograms of
lysate was subjected to 8 to 12% SDS-PAGE and transferred onto polyvi-
nylidene difluoride membranes. Filters were blocked in 0.1% casein in
PBS for 1 h and incubated with primary antibodies followed by probing
with fluorescence-labeled secondary antibodies (the Jackson Laboratory).
Proteins were detected with the Odyssey infrared imaging system
(LI-CORBiosciences). For immunoprecipitation, cells were culturedwith
M-CSF and RANKL for 2 to 3 days, starved in minimal essential medium
alpha (-MEM)without serum for 2 to 3 h, and treatedwithGST-RANKL
for the indicated times. Eight hundred micrograms of lysate protein was
incubated with 2 g primary antibody overnight. Protein A or G-agarose
(Sigma) beads were then added and incubated for 3 h. Beads were boiled
in 2 sodium dodecyl sulfate sample buffer for 5 min. After centrifuga-
tion, proteins were separated by 8% or 12% sodium dodecyl sulfate-poly-
acrylamide gels and Western blotted as described above.
Gradient centrifugation. Detergent-free density gradients were gen-
erated by the method ofMacdonald and Pike (17). Fractions were immu-
noblotted as described above.
Active small GTPase assays. Active Rac1 andRhoAweremeasured by
pulldown assay (Thermo Scientific, Pierce, Rockford, IL).
Statistics.All data are expressed asmeans standard deviations (SD),
and statistical significance was calculated by Student’s t test.
RESULTS
RANKL regulates the osteoclast cytoskeleton. RANKL’s induc-
tion of actin rings establishes the cytokine’s capacity to organize
the osteoclast cytoskeleton (3). To more precisely define this phe-
nomenon, we determined RANKL’s impact on the kinetics of
these structures. Thus, mature bone-residing osteoclasts were
washed in coldmedium to disrupt their actin rings. The cells were
then incubated, cytokine free, at 37°C for 30min, after which they
were exposed to RANKL or PBS for 15, 30, 60, or 120 min (13).
Osteoclasts, maintained consistently in RANKL, progressively re-
generate their actin rings, which are present in all cells after 2 h of
cytokine exposure (see Fig. S1 in the supplemental material). In
contrast, these cytoskeletal structures fail to appear in cells absent
the cytokine. Hence, in addition to its osteoclastogenic properties,
RANKL rapidly organizes the actin cytoskeleton of the mature
resorptive polykaryon.
c-Src associates with RANK in a RANKL-dependent manner.
c-Src is a key regulator of actin dynamics in osteoclasts (5, 12, 19).
It interacts with RANK at an undefined location within the recep-
tor’s carboxyl terminus, in dendritic cells, whose RANK content is
an order of magnitude greater than that of osteoclasts (26). To
explore the c-Src/RANK association in osteoclasts, spleen cells
were exposed to RANKL and M-CSF for 3 days, which commits
them to the resorptive cell’s phenotype. These prefusion osteo-
clasts were cytokine starved and treated with RANKL over time.
c-Src immunoprecipitates, immunoblotted for RANK and c-Src,
establish that the two interact in a RANKL-dependent manner
(Fig. 1A).
To explore the mechanisms by which RANKL promotes
RANK/c-Src association, we performed density gradient centrifu-
gation of lysates of cytokine-starved, prefusion osteoclasts ex-
posed to RANKL or carrier. RANK and c-Src were identified by
immunoblotting. In the absence of RANKL, its receptor and c-Src
are in different locations within the gradient (Fig. 1B). With cyto-
kine exposure, however, RANKmoves to the c-Src-rich fractions,
where the two proteins associate (Fig. 1C).
To determine if these phenomena obtain in fully differentiated
osteoclasts, we maintained spleen cells in the presence of M-CSF
and RANKL for 5 days, at which time they manifest the multinu-
cleated phenotype. Like prefusion osteoclasts, RANKL induces the
c-Src/RANK association and localizes the proteins in the same
intracellular fractions from which they coprecipitate (Fig. 1D, E,
and F).
c-Src SH2 and myristoylation domains dominate in RANK-
mediated cytoskeletal organization. c-Src impacts osteoclast
Izawa et al.
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function by phosphorylating effector molecules and via protein-
protein recognition. To characterize the key c-Src adaptor do-
main(s) mediating RANKL-stimulated cytoskeletal organization,
FLAG-taggedmutants of c-Src, lacking its amino-terminal myris-
toylation (MYR), SH2 (SH2), or SH3 (SH3) regions, were
retrovirally expressed in c-Src/ splenocytes (Fig. 2A). The cells
were differentiated into preosteoclasts, and equivalent levels of
expression of the various constructs were ensured by anti-FLAG
immunoblots (Fig. 2B). Similar results were obtained using the
anti-c-Src327 MAb, which recognizes all constructs except that
lacking the SH3 domain, which contains its epitope. Anti-FLAG
immunoprecipitates of virgin cells and those treated with RANKL
were immunoblotted for RANK and TRAF6 content. Although
somewhat less than wild-type (WT) c-Src, the SH3 mutant im-
munoprecipitates with RANK in a RANKL-dependent manner,
but the MYR and SH2 mutants fail to effectively recognize the
receptor (Fig. 2C). The inability of c-SrcSH2 to immunoprecipi-
tate with RANK, following RANKL exposure, is not due to altered
intracellular localization of the mutant kinase as density gradient
analysis shows comigration withWT c-Src, as well as withmutant
c-Src when its SH3 domain is absent (Fig. 2D). Deletion of the
MYRmotif, however, separates c-Src from RANK, but intracellu-
lar localization of the cytokine receptor is not affected by any c-Src
mutation. Finally, we asked if the kinase activity of c-Src impacts
its recognition of RANK.As seen in Fig. 2E, kinase-inactive, aswell
as constitutively active, c-Src associates with RANK as effectively
as the WT in RANKL-treated cells.
c-Src regulates the osteoclast cytoskeleton but not osteoclast
abundance. Activated RANK is believed to exert its antiapoptotic
effects, on osteoclasts, in conjunction with TRAF6 and c-Src. By
this scenario, the SH3 domain of c-Src recognizes TRAF6 (26),
which we confirm and establish is RANKL dependent (Fig. 2C).
To determine if the component of c-Src proposed to mediate
RANK-enhanced osteoclast survival is the same one organizing
the cell’s cytoskeleton, c-Src/ spleen cells transduced with
FLAG-tagged c-Src constructs were incubated with RANKL and
M-CSF. Staining for tartrate-resistant acid phosphatase (TRAP)
activity reveals no difference in numbers of c-Src/ osteoclasts
regardless of the construct with which they are transduced (Fig.
3A). As previously noted, however, c-Src/ cells fail to spread,
assuming a common phenotype of osteoclasts with cytoskeletal
dysfunction (29). Expectedly, themutant cell’s abnormal facade is
completely corrected by transduced WT c-Src. Absence of either
theMYR or SH2 domains, however, does not rescue the deranged
appearance of c-Src/ osteoclasts, indicating both motifs are re-
quired for organization of the cell’s cytoskeleton. While
c-SrcSH3 reduces the percentage of spread osteoclasts, its disor-
ganizing effect is substantially less than that from deletion ofMYR
or SH2. This conclusion is confirmed by the inability of MYR-
and SH2-bearing c-Src/ osteoclasts to resorb bone (Fig. 3B).
To ensure that the cytoskeletal effects of the various c-Srcmutants
do not reflect altered differentiation, we exposed the various
transductants to M-CSF and RANKL and temporally measured
osteoclastogenic makers. In fact, levels of expression of NFAT2,
the 3 integrin subunit, and cathepsin K are indistinguishable
regardless of the c-Src construct employed (Fig. 3C).
To further explore the means by which c-Src mediates cyto-
skeletal organization stimulated by the cytokine, we examined the
FIG 1 c-Src associates with RANK in a RANKL-dependent manner. Splenocytes were exposed to RANKL for 3 days to generate prefusion osteoclasts (A, B, and
C) or 5 days to produce fully differentiated, multinucleated osteoclasts (D, E, and F). Following 3 h or 1 h of incubation in cytokine-free medium, prefusion
osteoclasts ormature osteoclasts, respectively, were exposed to RANKLwith time. (A andD) c-Src immunoprecipitates (IP) were immunoblotted for RANK and
c-Src. (B and E) Lysates of cytokine-starved cells, exposed to RANKL or carrier for 30 min, were subjected to density gradient centrifugation. Fractions were
immunoblotted for RANK and c-Src. (C and F). Lysates were subjected to density gradient centrifugation, and c-Src immunoprecipitates of pooled fractions 12
to 15 were immunoblotted for RANK and c-Src. Results are representative of three independent experiments.
c-Src Links RANK/v3 to Osteoclast Cytoskeleton
July 2012 Volume 32 Number 14 mcb.asm.org 2945
 o
n








mutants’ impact on NF-B, ERK, and p38, which are canonical
signals activated via RANKL-RANK-TRAF6-dependent cascades.
Again, deletion of any c-Src domain does not alter RANKL acti-
vation of these molecules (Fig. 3D). Collectively, these data pro-
vide evidence that the principal means by which c-Src mediates
RANKL-stimulated cytoskeletal organization, compared to pro-
moting survival and differentiation, differ.
RANKL activates cytoskeleton-organizing proteins. c-Src is a
proximal component of a canonical cytoskeleton-organizing
complex activated by the v3 integrin, in osteoclasts. To deter-
mine if the same obtains in the context of RANKL, we exposed
c-Src/ spleen-derived, transduced macrophages to M-CSF and
RANKL for 5 days. These experiments were performed on the
osteoclast’s natural substrate, bone, which optimally activates cy-
toskeleton-organizing molecules in response to RANKL (see Fig.
S2 in the supplemental material). The cells were cytokine starved
and treated with RANKL for 20 min. c-Src activity, assessed by
Tyr416 phosphorylation, is enhanced by the cytokine, in FLAG-
tagged immunoprecipitates of c-Src/ preosteoclasts transduced
with theWTconstruct (Fig. 4A). The same occurs regarding phos-
phorylation of Syk, Slp76, and the relatively osteoclast-specific
GEF Vav3, all of which contribute to v3-stimulated cytoskele-
ton organization in osteoclasts (22, 29) (Fig. 4B, C, andD). Under
each circumstance, except Syk, the magnitude of RANKL stimu-
lation is somewhat less in c-SrcSH3-transduced than in WT-
transduced mutant cells. On the other hand, none of these mole-
cules are activated by RANKL in MYR- or SH2-expressing
cells.
RANKL’s capacity to phosphorylateVav3 in a c-Src-dependent
manner suggests that GEF’s target, Rac, which organizes the
osteoclast cytoskeleton as an v3-effector molecule, may also be
activated by the cytokine (6, 8). RANKL increasesGTP association
with Rac but not RhoA, in c-Src/ cells transduced with WT
c-Src or c-SrcSH3 but not that of the tyrosine kinase lacking its
MYR or SH2 domains (Fig. 4E and F). Similar to its upstream
activators, Rac1-GTP is less abundant in c-SrcSH3- than WT-
bearing cells. Thus, c-Srcmediates RANKL-induced osteoclast cy-
toskeleton organization principally via its SH2 motif, with some
contribution from its SH3 domain.
c-Src point mutants mirror domain deletion. The capacity of
c-SrcSH3 and c-SrcSH2 to continue to recognize target pro-
teins suggests they are conformationally intact (Fig. 2C). To con-
firm such is the case, however, we expressed inactivating FLAG-
tagged Myr (c-SrcG2A) (15, 21), SH3 (c-SrcW118K) (7), and SH2
(c-SrcR175L) (7, 27) point mutants in c-Src/ splenocytes (see
Fig. S3A in the supplemental material). Similar to their corre-
sponding domain-deleted constructs, c-SrcW118K, but not
c-SrcG2A or c-SrcR175L, continues to bind RANK (see Fig. S3B).
The same parallelism holds regarding osteoclast number and
spreading (see Fig. S4A in the supplemental material) as well as in
vitro bone resorptive capacity (see Fig. S4B), expression of osteo-
clast differentiation markers (see Fig. S4C) and activation of
osteoclastogenic signalingmolecules (see Fig. S4D). In a likeman-
ner, Myr and SH2 domain point mutants fail to activate cytoskel-
eton-organizing proteins, while that of SH3mirrorsWT c-Src (see
Fig. S5 in the supplemental material).
c-Src organizes the osteoclast cytoskeleton via RANK369 –373.
Having identified the cytoskeleton-organizing domain of c-Src
FIG2 c-SrcN-terminalmyristoylated region and SH2domainmediate RANKassociation. (A)WTandmutated c-Src constructs. (B) Lysates of c-Src/ splenic
macrophages, retrovirally transduced with empty vector or FLAG-taggedWT,MYR,SH3, orSH2 c-Src, were immunoblotted with anti-FLAG or anti-c-Src
MAb. (C) Cytokine-starved c-Src/ preosteoclasts, retrovirally transduced with empty vector (Vect) or FLAG-taggedWT,MYR,SH3, orSH2 c-Src, were
maintainedRANKL for 30min. FLAG immunoprecipitates were immunoblotted for RANK, TRAF6, or FLAG. (D) Cytokine-starved c-Src/ preosteoclasts,
transducedwith vector or FLAG-taggedWT,MYR,SH3, orSH2 c-Src, were treatedRANKL for 30min. Lysates were subjected to gradient centrifugation,
and the fractions were immunoblotted for FLAG or RANK. (E) c-Src/ preosteoclasts, transduced with vector or WT, kinase-inactive (KD) or constitutively
active (CA) c-Src, weremaintainedRANKL for 30min. c-Src immunoprecipitates were immunoblotted for RANK or c-Src. Results are representative of three
independent experiments.
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FIG 3 c-Src N-terminal myristoylated region and SH2 domain principally organize the osteoclast cytoskeleton but do not regulate differentiation. (A) Spleen
cells of Src/mice, transduced with c-Src domain deletion mutants, were cultured with M-CSF and RANKL for 7 days, after which the cells were stained for
TRAP activity. The total number of osteoclasts (OC) and those spread were counted. Vect, vector. *, P	 0.05. Scale bar, 200m. The data are shown asmeans
SD of triplicate samples. (B) Transduced osteoclasts, generated on bone, were removed after 5 days. Resorptive lacunae were stained by lectin (brown reaction
product outlined), and pit area was determined. *, P	 0.05. Scale bar, 200 m. The data are shown as means SD of triplicate samples. (C) c-Src/ splenic
macrophages, transduced with either empty vector or WT, MYR, SH3, or SH2 c-Src, were cultured in RANKL and M-CSF over time. Osteoclast differen-
tiation markers were determined by immunoblotting. Actin serves as a loading control. Flag, anti-FLAG antibody. (D) c-Src/ splenic macrophages,
transduced as in panel C, were cultured in RANKL andM-CSF for 3 days. The cells were cytokine starved and exposed to RANKLwith time. Signalingmolecules
were identified by immunoblotting. Actin serves as loading control. Results are representative of three independent experiments.
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recognizing RANK, we turned to the component of the receptor
binding the kinase. This exercise is challenged, in primary oste-
oclastic cells, by the presence of endogenous RANK, which, upon
cytokine stimulation, would compete with exogenous RANK for
c-Src association. We therefore transduced WT bone marrow
macrophages (BMMs) with retroviral vectors coding for various
components of the RANK cytoplasmic region linked to the exter-
nal domain of the human Fas (hFas) receptor (16, 28). The RANK
cytoplasmic domains of these chimeric constructs were designed
such that each contains only one of six intact putative TRAF bind-
ingmotifs (PTMs) (28) (see Fig. S6 in the supplemental material).
Mutation of all six PTMs served as a negative control. Lysates of
BMMs transduced with each chimeric construct were immuno-
blotted with the hFas MAb, which does not recognize the murine
protein, to ensure equivalent expression (Fig. 5A). The cells were
cultured with M-CSF and RANKL for 6 days to activate endoge-
nous receptors, resulting in formation of characteristic osteoclasts
by each transductant (Fig. 5B). After actin ring disruption, on
bone, the cells were incubated in cytokine-free medium at 37°C
for 30 min, after which they were exposed to hFas MAb, which
activates the chimeric receptors but notmurine Fas. Actin ring refor-
mation was determined over time. Only RANK PTMW3369–373 is
sufficient to organize the osteoclast cytoskeleton as manifested by
actin ring development (Fig. 5C).
To determine if RANK’s cytoskeleton-organizing motif,
PTMW3, which binds TRAF6, also recognizes c-Src, hFas/RANK-
transduced, serum- and cytokine-starved prefusion osteoclasts
were maintained, with or without hFas activating antibody, for 20
min. c-Src immunoprecipitates were then immunoblotted for
hFas. Similar to its cytoskeleton-organizing properties, RANK
PTMW3 is the only mutant chimeric construct whose binding of
c-Src is enhanced by the antibody (Fig. 5D). Furthermore, the
quantities of c-Src present in hFas immunoblots are similar in
vector- and WT chimera-transduced cells. Thus, unlike the v3
integrin, the RANK cytoplasmic domain does not constitutively
recognize the tyrosine kinase (29). Finally, confirming that RANK
PTMW3 is the receptor’s cytoskeleton-organizing motif, it is suf-
ficient to activate c-Src, Vav3, and Rac (Fig. 5E).
c-Src/RANK association, in osteoclasts, is v3 integrin de-
pendent. Osteoclasts lacking c-Src or the v3 integrin exhibit
features of cytoskeletal dysfunction, and we find the same obtains
whenRANK signaling is deficient inmature cells (see Fig. S1 in the
supplemental material). These observations prompted us to ask
whether the two molecules are functionally related in osteoclasts.
Thus, we exposed WT and 3/ BMMs to M-CSF and RANKL
for 3 days. Following cytokine starvation, the cells were RANKL
stimulated with time and c-Src immunoprecipitates were immu-
noblotted for RANK.Whereas, the cytokine rapidly induces c-Src/
RANK recognition in WT cells, this association is markedly re-
duced absent v3 (Fig. 6A). To confirm the integrin’s role in
mediating this interaction, we transduced 3/ BMMs with
empty vector or human 3 (h3). The human construct was cho-
sen as its cytoplasmic motif is identical to that of its murine coun-
terpart and an immunoprecipitating MAb recognizing its extra-
cellular domain is available (29). Importantly, we have established
that these transductants express physiological quantities of v3
(11). h3- and vector-bearing cells were cultured with RANKL
andM-CSF for 4 days, after which c-Src immunoprecipitates were
again immunoblotted for RANK. WT h3 rescues the inability of
3/ osteoclasts to spread while also restoring the RANKL-stim-
ulated c-Src/RANK association (Fig. 6B). To determine if c-Src/
RANK recognition requires activated v3, we cytokine starved
WT prefusion osteoclasts for 3 h. The cells were then maintained
in suspension or plated on the integrin’s ligand, vitronectin, for 30
FIG 4 RANKL activates cytoskeleton-organizing molecules principally via
c-Src MYR and SH2 domains. (A) c-Src/ spleen-derived macrophages,
transduced with either FLAG-tagged WT Src, MYR, SH3, or SH2 were
cultured with RANKL and M-CSF for 5 days on bone powder. Serum- and
cytokine-starved cells were exposed to RANKL (100 ng/ml) for 20 min. Phos-
phorylated c-SrcY416 and FLAG in FLAG immunoprecipitates (IP) (A), phos-
photyrosine (p-Y) and SLP-76 in SLP-76 immunoprecipitates (B), phospho-
tyrosine and Syk in Syk immunoprecipitates (C), and phosphotyrosine and
Vav3 in Vav3 immunoprecipitates (D) were determined by immunoblotting.
Rac1-GTP (E) and RhoA-GTP (F) were detected by pulldown assay, and total
GTPase was detected by immunoblotting. Densitometric data are expressed
relative to vector (Vect)/RANKL. The experiments were repeated twice.
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FIG 5 c-Src binds RANK369–373. (A) hFas expression in WT BMMs transfected with hFas/RANK WT, W1, W2, W3, W4, W5, W6, and P1-6, determined by
immunoblotting. Results are representative of three independent experiments. Vect, vector; hFas, anti-hFas antibody. (B) WT BMMs transfected with
Fas/RANK constructs were exposed toM-CSF andRANKL for 3 days on plastic and stained for TRAP activity. Scale bar, 200m. (C)WTBMMs transfectedwith
hFas/RANK constructs were culturedwith RANKL andM-CSF on bone for 6 days. The cells were washedwith coldmedium to disrupt actin rings and stimulated
with hFas MAb for 30 or 120 min. The percentage of osteoclasts with actin rings was determined. Scale bar, 100 m. The data are shown as means  SD of
triplicate samples. (D) WT BMMs transduced with hFas/RANK constructs were cultured with M-CSF and RANKL for 3 days. They were cytokine starved and
stimulated for 20 min by hFas MAb. c-Src immunoprecipitates (IP) and total cell lysate (TCL) were immunoblotted for hFas and c-Src. (E) WT BMMs
transduced with hFas/RANK constructs were cultured withM-CSF and RANKL for 3 days. Cytokine-starved cells were stimulated for 5 or 20min by hFasMAb.
Lysates were immunoblotted for c-SrcY416 and c-Src. Vav3 immunoprecipitates were immunoblotted for phosphotyrosine andVav3. Rac1-GTP and RhoA-GTP
were detected by pulldown assay, and the total abundance of the GTPases was determined by immunoblotting. Results are representative of three independent
experiments.
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min, which activatesv3-induced cytoskeleton-organizingmol-
ecules. As demonstrated by immunoblotting of c-Src immuno-
precipitates for RANK, only liganded v3 promotes association
of the two proteins (Fig. 6C).
c-Src links RANK and v3. It appears, therefore, that v3
andRANKpartner to activate a key cytoskeleton-organizing path-
way in osteoclasts, suggesting the twomoleculesmay associate. To
determine if such is the case, we temporally exposed hFas/RANK-
bearingWTosteoclasts to the hFasMAb. Immunoblotting of hFas
immunoprecipitates for the 3 subunit demonstrates that ac-
tivated RANK progressively associates with v3 (Fig. 7A).
Furthermore, this interaction is obviated in the absence of c-
Src (Fig. 7B).
The dependency of v3/RANK association on c-Src raised
the possibility that the kinase links the two receptors. In this
circumstance, the component of c-Src binding the integrin
should differ from that recognizing RANK. Thus, we trans-
duced c-Src/ splenic macrophages with FLAG-tagged c-Src
deletion (Fig. 7C) or point mutants (Fig. 7D) and differentiated
them into prefusion osteoclasts. Lysates were immunoprecipi-
tated with FLAG MAb, and the product was immunoblotted
for the 3 subunit. Similar to its association with RANK, c-Src
requires an intact MYR domain to recognize 3. On the other
hand, the 3/c-Src interaction, in osteoclasts, as in other cir-
cumstances (1), is unimpaired by absence or mutation of SH2
but aborted by SH3 or c-SrcW118K.
These observations suggest a model whereby c-Src, by its SH3
region interacting with v3 and its SH2 domain binding RANK,
links the two receptors. Deletion or inactivation of either SH re-
gion should therefore obviatev3/RANKassociation.Hence, we
transfectedHEK293T cells withWTh3, various combinations of
FLAG-tagged c-Src deletion mutants, and HA-RANK. In fact,
RANK and the integrin coprecipitate in the presence of WT c-Src
but not in the absence of its MYR, SH2, or SH3 domain (Fig. 7E).
To determine if the c-Src-mediated v3/RANK association re-
quires activation of the cytokine receptor, we transfected
HEK393T cells with WT hFas/RANK (Fig. 7F). We once again
ensured conformational integrity of the deletion constructs by
expressing c-Src point mutants in the same cells. Whereas irrele-
vant IgG has no effect, activation with anti-Fas MAb yields hFas/
RANK association only with WT c-Src. Alternatively, point mu-
tation of any of the three domains obviates this interaction. Thus,
v3 and RANK are linked by c-Src only upon activation of the
cytokine receptor.
Finally, we turned to the consequences of c-Src domain dele-
tion (Fig. 7G) or mutation (Fig. 7H) on RANKL- or integrin-
mediated RANK/c-Src binding. Once again establishing a central
role for integrin occupancy, interaction between the cytokine re-
ceptor and tyrosine kinase is undetectable in all nonadherent
transduced cells.While RANKL enhances RANK/c-Src binding in
adherent WT cells, it fails to do so in the face of Myr or SH2
domain deletion or mutation. In keeping with partial recognition
of c-Src by activated RANK, absent v3 (Fig. 6A), RANKLmod-
estly promotes this interaction in transduced cells lacking an in-
tact SH3 motif.
DISCUSSION
The osteoclast cytoskeleton is a unique structure, which creates a
resorptive microenvironment and delivers bone-degrading mole-
cules into this extracellular space enclosed by actin rings. These
FIG 6 c-Src binding to RANK is v3 dependent. (A) Cytokine-starved WT and 3/ preosteoclasts were exposed to RANKL for the times shown. c-Src
immunoprecipitates (IP) and total cell lysate (TCL) were immunoblotted for RANK, the 3 subunit, and c-Src. (B) 3/ BMMs were retrovirally transduced
with h3 or vector. After 4 days in RANKL and M-CSF, cytokine-starved cells were exposed to RANKL for the times shown. The cells were stained for TRAP
activity (left panel). c-Src immunoprecipitates and TCL were immunoblotted for RANK, 3 subunit, and c-Src (right panel). Scale bar, 200 m. (C) Cytokine-
starvedWT preosteoclasts were maintained in suspension (S) or plated on vitronectin (A) for 30 min. c-Src immunoprecipitates and TCL were immunoblotted
for RANK and c-Src. Results are representative of three independent experiments.
Izawa et al.
2950 mcb.asm.org Molecular and Cellular Biology
 o
n








circular sealing zones are the products of redistribution of podo-
somes, arranged in clusters in non-bone-residing cells. Upon at-
tachment tomineralized substrate, these transient adhesion struc-
turesmigrate to the bone-apposed plasmamembrane, where in an
actin-rich environment, they encompass the matrix surface to be
degraded. Thus, actin ring formation, which requires RANKL, is
key to organizing the osteoclast cytoskeleton to its resorptive con-
formation.
Although the general morphological features of osteoclast po-
larization have been long appreciated, insights into the relevant
molecular mechanisms are recent. Signals emanating from ligan-
ded v3 activate a complex in which constitutively associated
c-Src is the most proximal, established component (29). Inactiva-
tion of any of the complex-residing proteins yields poorly spread
“crenated-appearing” osteoclasts due to cytoskeletal dysfunction.
The promacrophage proliferative cytokineM-CSF, which also or-
ganizes the osteoclast cytoskeleton, does so by targeting the same
signaling molecules as v3 (8, 30). Furthermore, M-CSF-medi-
ated activation of Rac, which is essential for osteoclast cytoskeletal
remodeling and function, requires this integrin (8). Thus, v3
and the macrophage-proliferating cytokine collaborate in orga-
nizing the osteoclast cytoskeleton in a c-Src-dependent manner.
The discovery that RANKL is the key osteoclastogenic cytokine
provided the seminal insights into the mechanisms of bone re-
sorption. This observation permitted generation of osteoclasts in
vitro, enabling dissection of the means by which macrophages
differentiate intomature resorptive cells. An unexpected outcome
of these studies is the finding that RANKL also enhances osteoclast
function by organizing the cell’s cytoskeleton (3). However, the
mechanisms mediating RANKL stimulation of the mature cell re-
mained elusive.
We have established that like M-CSF, RANKL partners with
v3 to organize the osteoclast cytoskeleton. Perhaps the most
compelling aspect of this scenario is the realization that this integ-
rin-cytokine collaboration involves their interaction, wherein c-
Src links the two receptors. These observations not only shed light
on the heretofore elusive means by which RANKL stimulates the
mature osteoclast to resorb bone but also provide insights into
how c-Src mediates cytoskeleton organization in the bone resorp-
tive process.
In osteoclasts, c-Src constitutively binds v3, which activates
the tyrosine kinase upon integrin occupancy. The same is not true
regarding c-Src association with RANK (29). In fact, RANKL in-
duces RANK/c-Src recognition, in authentic osteoclasts, only in
the presence of v3 activated by ligand, in an outside-inmanner
and is enhanced by the osteoclastogenic cytokine.
The biological implications of RANK/c-Src association are,
however, controversial. RANK does not possess kinase activity,
and Wong et al. conclude that its antiapoptotic properties reflect
delivery of c-Src, via its SH3 domain, to the receptor by TRAF6, an
adaptor protein essential for osteoclastogenesis (26). The logical
consequence of this scenario should be decreased osteoclast num-
ber in the face of c-Src deficiency, which is, however, inconsistent
with their enhanced abundance in c-Src/ mice (2). Further-
FIG 7 c-Src links RANK and v3. (A) WT preosteoclasts, transduced with WT hFas/RANK, were exposed to hFas MAb for the times shown. hFas immuno-
precipitates (IP) were immunoblotted for 3 subunit and hFas. (B) WT and c-Src/ preosteoclasts, transduced with WT hFas/RANK, were exposed to hFas
MAb with time. hFas immunoprecipitates were immunoblotted for the 3 subunit and hFas. (C) Lysates of c-Src/ preosteoclasts transduced with FLAG-
tagged c-Src domain deletion constructs were immunoprecipitated with anti-FLAGMAb, and the product was immunoblotted for 3 subunit and FLAG. Vect,
vector. (D) Lysates of c-Src/ preosteoclasts transduced with FLAG-tagged c-Src point mutants were immunoprecipitated with anti-FLAG MAb, and the
product was immunoblotted for the3 subunit and FLAG. (E)HEK293T cells were transfected with FLAG-tagged c-Src constructs, HA-tagged RANK, and h3.
HA immunoprecipitates were immunoblotted for h3 andHA. (F) Cytokine-starved c-Src/ preosteoclasts transducedwith FLAG-tagged c-Src pointmutants
and WT hFas/RANK were exposed to hFas MAb for 20 min. hFas immunoprecipitates were immunoblotted for 3 subunit and hFas. (G) Cytokine-starved,
c-Src/ prefusion osteoclasts, transduced with FLAG-tagged c-Src domain-deleted constructs, were maintained in suspension (S) or plated on vitronectin (A)
for 30 min  RANKL. FLAG immunoprecipitates were immunoblotted for RANK and FLAG. WB, Western blot. (H) Cytokine-starved, c-Src/ prefusion
osteoclasts, transduced with FLAG-tagged c-Src point mutants, were maintained in suspension (S) or plated on vitronectin (A) for 30 min  RANKL. FLAG
immunoprecipitates were immunoblotted for RANK and FLAG. The experiments were repeated 2 or 3 times with similar results.
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more, absence of the SH2, SH3, orMYRdomain does not dampen
RANKL activation of its osteoclastogenic effector molecules. De-
spite their association, which we confirm, the c-Src/TRAF6 com-
posite, therefore, does not appear to regulate RANK’s osteoclas-
togenic properties. On the other hand, the requirement for the
c-Src SH2 domain for RANK association supports the concept
that the tyrosine kinase in osteoclasts functions exclusively to or-
ganize their cytoskeleton. While SH2 profoundly affects signals
consequent to RANK/c-Src association, the SH3motif also partic-
ipates, as evidenced by partial cytoskeletal disruption and some
degree of impaired signaling in its absence.
Having established, with deletion and point mutants, that the
SH2 domain of c-Src mediates RANK recognition, we asked
which component of the cytokine receptor binds the kinase. Using
chimeric constructs, in which RANK signaling is activated by hFas
antibody, we find that a component of a single TRAF-interacting
site is sufficient to organize the osteoclast cytoskeleton, promote
RANK/c-Src recognition, and activate the same key cytoskeleton-
organizing molecules as v3 and c-Fms. Because SH2 domains
classically bind phosphorylated tyrosines, we were surprised that
no such residues are present in the region of RANK recognizing
c-Src.While this observation suggests an indirect interaction, SH2
domains in other proteins may recognize binding partners by
phosphotyrosine-free, surface-surface contact (4). The same non-
canonical paradigm holds in the context of c-SrcSH3 recognizing
the 3 cytoplasmic domain, which occurs in the absence of a pro-
line-rich motif (1).
Our data suggest an interactive model between RANK, c-Src,
and v3 in organizing the osteoclast cytoskeleton (Fig. 8). In its
nonliganded state, RANK resides in a plasma membrane region
distinct from that containing c-Src. Upon RANKL stimulation,
the receptor transits to a c-Src-rich domain, where in the presence
of activated v3, it associates with the SH2 motif of the tyrosine
kinase. RANKL partially induces RANK/c-Src recognition in the
absence of the c-Src SH3 region, which constitutively complexes
the integrin and is necessary for optimal osteoclast cytoskeletal
organization, likely because it links the two receptors. Thus, we
propose that activated RANK prompts two distinct signaling
pathways: one, which is c-Src and v3 independent, promotes
osteoclast formation, and the other, in which the tyrosine kinase
and integrin are required, organizes the cell’s cytoskeleton and
stimulates its resorptive capacity.
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